Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer

Collaboration leverages Quotient’s platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases Quotient and Pioneering Medicines, Flagship’s in-house drug development unit, will jointly conduct research activities Agreement initiated…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.